These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 18185143

  • 1. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study.
    Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS.
    Retina; 2008 Jan; 28(1):85-93. PubMed ID: 18185143
    [Abstract] [Full Text] [Related]

  • 2. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
    Chan WM, Lai TY, Lai RY, Liu DT, Lam DS.
    Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401
    [Abstract] [Full Text] [Related]

  • 3. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.
    Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS.
    Br J Ophthalmol; 2006 Jul; 90(7):869-74. PubMed ID: 16597666
    [Abstract] [Full Text] [Related]

  • 4. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M.
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [Abstract] [Full Text] [Related]

  • 5. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB, Mohr JK, Ossewaarde-van Norel A, den Hollander AI, Keunen JE, Hoyng CB, Boon CJ.
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [Abstract] [Full Text] [Related]

  • 6. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
    Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, Tsang CW, Brelén ME.
    Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
    [Abstract] [Full Text] [Related]

  • 7. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
    Cornut PL, Quaranta-El Maftouhi M, Mauget-Faÿsse M.
    J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
    [Abstract] [Full Text] [Related]

  • 8. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y, Zhou P, Pan CT, Zhang L, Liu P, Zhou H, Jiao X, Xiong Y, Tian R, Lu Y, Yu X, Li X.
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [Abstract] [Full Text] [Related]

  • 9. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study.
    Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, Klancnik JM, Aizman A.
    Retina; 2003 Jun; 23(3):288-98. PubMed ID: 12824827
    [Abstract] [Full Text] [Related]

  • 10. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK, Chang CK, Peng CH.
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [Abstract] [Full Text] [Related]

  • 11. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
    Nicolò M, Zoli D, Musolino M, Traverso CE.
    Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
    [Abstract] [Full Text] [Related]

  • 12. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y, Li L, Xu G, Wang W.
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M.
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
    Lai TY, Wong RL, Chan WM.
    Trans Am Ophthalmol Soc; 2015 Jun; 113():T8. PubMed ID: 26755855
    [Abstract] [Full Text] [Related]

  • 17. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V, Purtskhvanidze K, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [Abstract] [Full Text] [Related]

  • 18. Photodynamic therapy for chronic central serous chorioretinopathy.
    Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM.
    Retina; 2003 Dec; 23(6):752-63. PubMed ID: 14707823
    [Abstract] [Full Text] [Related]

  • 19. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F.
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [Abstract] [Full Text] [Related]

  • 20. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V, Vysloužilová D, Uher M.
    Semin Ophthalmol; 2018 May; 33(5):690-699. PubMed ID: 29252091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.